Project

NANOTRANSMED

Goal: NANOTRANSMED is a European project, led by a french-german-swiss consortium and cofinanced by the INTERREG VA Upper Rhine Programme.
This project enables French, German and Swiss scientists to develop together applications and innovations in nanomedicine.
The NANOTRANSMED consortium focuses in particular on issues concerning early, reliable and fast diagnosis but also personalized treatment of diseases such as cancers and inflammation as well as issues regarding nosocomial infections contracted by 5% of hospitalized patients.
More informations on www.nanotransmed.eu

Date: 1 November 2016 - 31 October 2019

Updates
0 new
11
Recommendations
0 new
10
Followers
0 new
35
Reads
0 new
528

Project log

Delphine Felder-Flesch
added an update
Congratulations to our colleagues Roland and Shirley form the Universities of Mainz Medical Center and Duisburg-Essen for their great paper in PNAS.
 
Delphine Felder-Flesch
added an update
On 2 May the European Commission announced the proposed budget of €100 billion and the name of the next EU Research & Innovation Framework Programme : Horizon Europe (2021-2027).
 
Delphine Felder-Flesch
added an update
Delphine Felder-Flesch présentera le potentiel des nanoparticules d'oxyde de fer dendronisées en imagerie moléculaire et thérapie.
 
Delphine Felder-Flesch
added 2 research items
The synthesis of small-size dendrons and their grafting at the surface of iron oxide nanoparticles were achieved with the double objective to obtain a good colloidal stability with a mean hydrodynamic diameter smaller than 100 nm and to ensure the possibility of tuning the organic coating characteristics including morphology, functionalities, physico-chemical properties, grafting of fluorescent or targeting molecules. Magnetic resonance and fluorescence imaging are then demonstrated to be simultaneously possible using such versatile superparamagnetic iron oxide nanocrystals covered by a dendritic shell displaying either carboxylate or ammonium groups at their periphery which could be further labelled with a fluorescent dye. The grafting conditions of these functionalized dendrons at the surface of SPIO NPs synthesized by co-precipitation have been optimized as a function of the nature of the peripheral functional group. The colloidal stability has been investigated in water and osmolar media, and in vitro and in vivo MRI and optical imaging measurements have been performed showing encouraging biodistribution.
Delphine Felder-Flesch
added 2 research items
This chapter discusses the synthesis, functionalization, characterization, and imaging applications of iron-oxide-nanoparticle-based contrast agents. By reducing the size from bulk to the nanometer scale (<20 nm), ferrimagnetic iron oxide acquires a magnetic property called superparamagnetism, which is key to the potential of these particles as MRI contrast agents. This chapter describes the theory governing the relaxivity of nanoparticle-based contrast agents. The different syntheses, coatings, and functionalization approaches are then discussed, including how these syntheses affect the properties of the nanomaterial. Different techniques for the characterization of the cores and coatings of nanoparticles, including their size and composition, are then discussed. Particular attention is given to characterization of the magnetic properties of iron oxide nanoparticles. Finally, the acquisition of MRI phantoms is presented.
The biodistribution of dendronized iron oxides, NPs10@D1_DOTAGA and melanin-targeting NPs10@D1_ICF_DOTAGA, was studied in vivo using MRI and planar scintigraphy through [177Lu]Lu-radiolabeling. MRI experiments showed high contrast power of both dendronized nanoparticles (DPs) and hepatobiliary and urinary excretions. Little tumor uptake could be highlighted after intravenous injection probably as a consequence of the negatively charged DOTAGA-derivatized shell which reduces the diffusion across the cells’ membrane. Planar scintigraphy images demonstrated a moderate specific tumor uptake of melanoma-targeted [177Lu]Lu-NPs10@D1_ICF_DOTAGA at 2 h post intravenous injection, and the highest tumor uptake of the control probe [177Lu]Lu-NPs10@D1_DOTAGA at 30min pi, probably due to the enhanced permeability and retention (EPR) effect. In addition, ex vivo Confocal microscopy (EVCM) studies showed a high specific targeting of human melanoma samples impregnated with NPs10@D1_ICF_Alexa647_ DOTAGA.
Delphine Felder-Flesch
added an update
Dear colleagues,
We are delighted to announce the forthcoming E-MRS 2018 Symposium E "Nanotechnology for targeted medicines and theranostics" which will take place in Strasbourg (France) from June 20th to 22nd 2018 during the E-MRS SPRING 2018 global symposium (www.european-mrs.com) https://www.european-mrs.com/nanotechnology-targeted-personalized-medicines-and-theranostics-emrs You are now invited to submit abstracts at the following link: https://www.european-mrs.com/user/login?destination=extranet/new-abstract/1382/0
Deadline for abstract submission is January 18, 2018
Application form for the Symposium E student award (450 euros) can be found at http://www.european-mrs.com Hot topics to be covered by the symposium E
  • Medical imaging
  • Theranostics
  • Targeted and personalized nanomedicines
  • Immunotherapies through nano
  • Nanoparticles for clinical imaging and therapy
  • Translation of targeted nanomedicines
  • Nanomaterials in Oncology
  • Understanding the Nano-Bio interactions
  • Multitherapies
  • Magnetic hyperthermia and photodynamic therapies
  • Drug delivery nano-systems
  • Targeted in vivo SiRNA delivery
  • Nano-targeting to cells and tissues
  • Nanomaterial crosstalk with pathogens
 
Charlotte Raoul
added an update
NANOTRANSMED at #MatChem13 #MC13 last week in Liverpool! Dendronized superparamagnetic nanoparticles as tools for MRI, efficient in vivo cancer targeting and magnetic hyperthermia treatment were presented by Dinh-Vu Nguyen
 
Delphine Felder-Flesch
added an update
The Nanotransmed website has been launched!
 
Delphine Felder-Flesch
added 2 research items
We report herein the synthesis of biocompatible small-sized phosphonated monomers and dendrons used as functional coatings of metal oxide nanoparticles, more specifically superparamagnetic iron oxides (SPIOs) for magnetic resonance imaging (MRI) and therapy through hyperthermia. The molecules were engineered to modulate their size, their hydrophilic and/or biocompatible character (poly(amido)amine versus oligoethyleneglycol), the number of anchoring phosphonate groups (monophosphonate versus phosphonic tweezers) and the number of peripheral functional groups for further grafting of dyes or specific vectors. Such a library of hydrophilic phosphonic acids opens new possibilities for the investigation of dendronized nanohybrids as theranostics.
Charlotte Raoul
added an update
NANOTRANSMED’s new Website is online! Discover all information about the project, partners, activities on www.nanotransmed.eu !
NANOTRANSMED lance son site web ! Venez découvrir le projet, les partenaires et leurs activités sur www.nanotransmed.eu !
NANOTRANSMED eröffnet seinen Webseite ! Entdecken Sie das Projekt und die Partner auf www.nanotransmed.eu !
 
Delphine Felder-Flesch
added an update
Our colleague, Dr. Arnaud Scherberich, from the Department of Biomedicine, Uni Basel, (https://biomedizin.unibas.ch/nc/fr/about-us/people/profil/profile/person/scherberich/) was appointed a member of the executive committee of the Swiss Society for Biomaterials and Regenerative Medicine (https://ssbrm.ch/). Congratulations Arnaud!
 
Delphine Felder-Flesch
added a research item
Nanomedicine can take advantage of the recent developments in nanobiotechnology research areas for the creation of platforms with superior drug carrier capabilities, selective responsiveness to the environment, unique contrast enhancement profiles and improved accumulation at the disease site. Colloidal inorganic nanoparticles (NPs) have been attracting considerable interest in biomedicine, from drug and gene delivery to imaging, sensing and diagnostics. It is essential to modify the NPs surface to have enhanced biocompatibility and reach multifunctional systems for the in vitro and in vivo applications, especially in delivering drugs locally and recognizing overexpressed biomolecules. This paper describes the rational design for dendrimer-nanoparticle conjugates elaboration and reviews their state-of-the-art uses as efficient nanomedicine tools.
Delphine Felder-Flesch
added an update
The scientists of the NANOTRANSMED consortium rely on a “multifunctional” approach, based on the dendritic materials technology. The aim is to graft polyvalent branched molecules – dendrimers – on a substrate in order to create multi-functional objects or surfaces. These dendritic molecules can be synthetized in a controlled and iterative manner. Moreover their architecture can easily be tuned to solve different issues as regards to biocompatibility, bioelimination or targeting.
The researchers aim at developing, designing and improving biocompatible and innovative nano-objects (circulating probes or implant’ coatings) by conferring them:
- Specific targeting capacities
- Antibacterial properties
- Enhanced in vivo stability
- Furtivity in order to escape the RES
- Reduced toxicity.
The objectives of the project in terms of improved patients’ care thanks to nanomedicine are the following:
- Establish an early, fast and reliable diagnosis by improving the targeting efficiency of imaging probes to diagnose diseases such as cancer, inflammation
- Deliver a personalized treatment, by the development of theranostic nano-objects, i. e. capable of combining efficiently targeted treatment and therapy monitoring by imaging,
- To fight nosocomial infections linked to invasive interventions requiring a medical device (catheter, probes, ENT implants, vascular, cardiac ...). Many implants must display smart antibacterial surfaces to avoid microbial colonization.
These new probes and implant coatings will be directly used at the end of the project by the Hospitals of Basel and Freiburg associated to this project and conducting preclinical studies, as well as by any company, biotech or equipment supplier in the field of diagnosis and therapy, or implantology (valves, pacemakers, cardiac defibrillators).
The resulting innovations of this multidisciplinary consortium of complementary expertises will allow a national and international scientific outreach of the RMT in the field of nanomedicine.
Communication and dissemination actions of generated knowledge and developed innovations are planned in order to contribute to the valorization of the project towards the scientific community, the business world and the general public, not only at the Upper Rhine Region level but also at the European and international levels.
 
Delphine Felder-Flesch
added 5 project references
Charlotte Raoul
added a project goal
NANOTRANSMED is a European project, led by a french-german-swiss consortium and cofinanced by the INTERREG VA Upper Rhine Programme.
This project enables French, German and Swiss scientists to develop together applications and innovations in nanomedicine.
The NANOTRANSMED consortium focuses in particular on issues concerning early, reliable and fast diagnosis but also personalized treatment of diseases such as cancers and inflammation as well as issues regarding nosocomial infections contracted by 5% of hospitalized patients.
More informations on www.nanotransmed.eu